-
December 08, 2010
Stryker finally rids itself of a long-failed product. Find out if this othopedic devices manufacturer is poised for ...
-
December 03, 2010
Merck is making an exciting bet on a possible diabetes breakthrough.
-
November 24, 2010
Wall Street is giving no credit to a very well-run franchise.
-
November 16, 2010
A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
-
November 03, 2010
Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick ...
-
November 02, 2010
A once-dependable growth stock disappoints, and pays for it.
-
October 25, 2010
At the current time, finding investment appeal in Johnson & Johnson's stock is difficult.
-
October 21, 2010
Boston Scientific is priced to do almost nothing, but that may underestimate the potential of operating improvement.
-
October 21, 2010
St. Jude is holding its own, but investors will demand more if the stock is to outperform.
-
October 19, 2010
St. Jude pays big price tag, but gets a potential blockbuster in return.
-
September 22, 2010
New advances in medical devices will not only help patients live better lives, but they'll power portfolios as well.
-
September 20, 2010
Are you concerned about valuation ratios when you make buy/sell decisions? Some of the numbers say there's no need ...
-
September 17, 2010
It may seem hopeless investing in stocks today, but some businesses thrive despite a bad housing market and high ...
-
August 26, 2010
It seems that the expectations for Medtronic are so low that long-term investors have little to fear.
-
August 26, 2010
A pessimistic stock market and weak Medtronic results have sent shares of Stryker back toward their lows over the ...
-
July 30, 2010
Sadly, diabetes is quickly becoming a global epidemic. Nearly 300 million people suffer from the disease worldwide.
-
July 22, 2010
It's difficult to find a catalyst for growth to return to more historical levels at Johnson & Johnson.
-
June 11, 2010
Market volatility over the past few years has presented M&A opportunities for best-in-breed companies.
-
June 01, 2010
Covidien made a surprising deal to get into peripheral vascular therapies - a business with big growth potential.
-
June 01, 2010
Can Intuitive Surgical produce the growth necessary to validate the stock's lofty perch?
